RITA (NSC 652287)诱导DNA-蛋白质和DNA-DNA交联,检测不到DNA单链断裂,通过靶向作用于p53,也抑制MDM2-p53相互作用。
RITA(NSC 652287) induced both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks. RITA, a drug that, like nutlin-3, can disrupt the p53/Mdm2 interaction.
30% propylene glycol, 5% Tween 80, 65% D5W(5%葡萄糖水溶液)
0.1 nM - 1 mM, 10 mM 储存于 DMSO
0.1 mg/kg, 1 mg/kg或10 mg/kg静脉注射或腹腔注射
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Rivera MI, et al. Biochem Pharmacol. 1999, 57(11), 1283-1295.
[2] Issaeva, N., et al. 2004. Nat. Med. 10: 1321-1328.
[3] Nieves-Neira, W., et al. 1999. Mol. Pharmacol. 56: 478-484.
分子式 C14H12O3S2 |
分子量 292.37 |
CAS号 213261-59-7 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 60 mg/mL |
Water <1 mg/mL |
Ethanol 8 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT03052036 | NSTEMI - Non-ST Segment Elevation MI | Procedure: Coronary Angiography|Procedure: Coronary revascularisation|Other: Optimal Medical Therapy | Newcastle-upon-Tyne Hospitals NHS Trust|British Heart Foundation|Newcastle University | 2016-10-01 | 2017-02-09 | |
NCT01524601 | Disorder Related to Renal Transplantation|Hypercholesterolemia | Drug: Rosuvastatin | University of Oslo School of Pharmacy|Oslo University Hospital | Phase 4 | 2012-02-01 | 2012-10-11 |
NCT01484691 | Asthma | Drug: Budesonide | University of California, San Francisco|National Heart, Lung, and Blood Institute (NHLBI) | 2011-10-01 | 2016-04-06 | |
NCT00523133 | Alcohol Dependence | Drug: naltrexone|Drug: naltrexone|Behavioral: Broad Spectrum Treatment|Behavioral: Motivational Enhancement Treatment | Indiana University School of Medicine|VA Boston Healthcare System|Brown University|George Washington University|Indiana University | Phase 2 | 2000-09-01 | 2007-08-30 |
NCT01051986 | Coronary Artery Disease | Procedure: saphenous vein composite grafting|Procedure: right internal thoracic artery composite grafting | Seoul National University Hospital | 2008-09-01 | 2013-11-21 | |
NCT03072199 | Ischemic Heart Disease|Myocardial Infarction|Inflammation | Drug: RiTUXimab Injection | Papworth Hospital NHS Foundation Trust | Phase 1|Phase 2 | 2017-03-13 | 2017-03-08 |
NCT00690703 | Non Small Cell Lung Cancer|Pulmonary Metastases | Device: RF ablation (Rita Medical Systems Model 1500x) | Angiodynamics, Inc. | Phase 2 | 2001-07-01 | 2008-06-04 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们